Ultragenyx's Q1 Loss Wider Than Expected, Revenues Increase Y/Y

Ultragenyx Pharmaceutical (RARE) reported first-quarter 2025 loss of $1.57 per share, wider than the Zacks Consensus Estimate of a loss of $1.54. The company had incurred a loss of $2.03 per share in the year-ago quarter.Ultragenyx’s total revenues amounted to $139.3 million in the reported quarter, up 28% year over year, on the back of higher product sales. The top line, however, missed the Zacks Consensus Estimate of $142 million. (See the Zacks Earnings Calendar to stay ahead of market-making news.)The c ...